Gastroenterology · Medical Literature
Modulation of Microbiota-Derived Bile Acids Linked to Symptom Amelioration in Crohn's Disease: Insights From a Randomized Clinical Trial With Xanthohumol Supplementation.
Abstract
Xanthohumol (XN), a dietary flavonoid from hops (Humulus lupulus), possesses anti-inflammatory and microbiome-modulatory properties with potential therapeutic benefits for Crohn's disease (CD). To investigate the effects of XN on the gut environment in CD, we conducted a randomized, placebo-controlled clinical trial-the XN Microbiome and Signature (XMaS) trial (NCT4590508). 19 participants with clinically active CD completed the study. They were randomized to receive 24 mg/day of XN or placebo for 8 weeks, with clinical assessments at baseline and every 2 weeks. We assessed changes to Crohn's disease activity index (CDAI) scores, systemic inflammation, gut barrier function, profiling of microbial metabolism of XN, and gut microbiota composition and metabolism. Integration analysis of gut microbiota abundance, fecal metabolites, and inflammatory markers with CDAI scores revealed a pattern in which reductions in secondary bile acids and increases in IL-10 were associated with improved CDAI score in XN-treated individuals. These findings suggest that XN beneficially modulates the gut environment in CD by influencing microbial bile acid metabolism and host inflammatory response, thereby improving symptoms in individuals with severe innate immune activation.
Clinical relevance
In adults with clinically active Crohn's disease, does 8 weeks of daily oral xanthohumol (24 mg/day) modulate gut microbiota composition and microbial bile acid metabolism in a manner associated with improvement in clinical disease activity as measured by the CDAI? __SNAPSHOT__ {"studyDesign":"Randomized, placebo-controlled clinical trial (Phase 2; triple-masked per protocol; the XMaS trial, NCT04590508)","setting":"Not reported (conducted under an Investigational New Drug application; United States, academic/integrative medicine setting inferred from principal investigator affiliations)","sampleSize":"n=19 participants with clinically active CD completed the study; individual arm sizes not reported in the abstract","population":"Adults with clinically active Crohn's disease (not in remission), non-smokers; concomitant anti-inflammatory supplements and frequent medication dose changes were exclusion criteria","intervention":"Xanthohumol (XN) 24 mg/day orally, encapsulated in a rice protein vehicle, taken once daily with the first meal, for 8 weeks","comparator":"Identical capsule containing rice protein vehicle alone (placebo), administered on the same schedule for 8 weeks","primaryOutcome":"Not explicitly designated as a single primary endpoint in the abstract; assessed outcomes included Crohn's Disease Activity Index (CDAI) scores, systemic inflammatory markers, gut barrier function, microbial metabolism of XN, gut microbiota composition, and fecal metabolite profiles, with integration analysis linking these to CDAI","followUp":"8 weeks, with clinical assessments at baseline and every 2 weeks","fundingSource":"Government (National Institutes of Health, National Center for Complementary and Integrative Medicine: R01 AT010271, R01 AT010271-02S1, K24AT011568); xanthohumol raw material provided by Hopsteiner; encapsulation by Metagenics, Inc."}
Key findings
Among the 19 completers, multi-omic integration analysis of gut microbiota abundance, fecal metabolites, and inflammatory markers revealed an associative pattern in XN-treated participants in which reductions in secondary bile acids and increases in IL-10 co-occurred with improvement in CDAI scores. No absolute CDAI values, inter-group differences, effect sizes, confidence intervals, p-values, or NNT/NNH are reported in the abstract. The direction and magnitude of CDAI change attributable specifically to XN versus placebo cannot be determined from the available abstract text. Adverse event profiles are not described in the abstract. These findings are presented as associative patterns identified through integrative multi-omic analysis rather than as pre-specified, inferentially tested primary endpoints.
Practice implications
This small Phase 2 pilot RCT provides preliminary, mechanistically plausible signal that xanthohumol may beneficially modulate the gut environment in Crohn's disease by influencing microbial secondary bile acid production and host IL-10 responses, both of which are biologically relevant to CD pathophysiology. However, the study established an association—not causation—between these biomarker changes and CDAI improvement. The trial was not powered to detect a statistically or clinically significant treatment effect on CDAI, and no between-group statistical comparisons are reported in the abstract. Which patients benefit most, the durability of any effect beyond 8 weeks, and whether observed changes translate to endoscopic healing or mucosal remission remain entirely unknown. Only 19 participants completed the trial; severely immunocompromised patients, pediatric patients, and patients on biologic therapies were likely not adequately represented. Importantly, only the abstract is available for this review, precluding assessment of full randomization procedures, dropout rates, concomitant medication use, and full statistical analyses—all of which are critical limitations of interpretation. Practice should not change on the basis of these findings. __LIMITATIONS__ Critically small sample (n=19 completers); the trial is explicitly described as a pilot study not powered to establish efficacy.,Arm-level sample sizes are not reported in the abstract, precluding assessment of balance or inferential statistical power.,No between-group p-values, confidence intervals, or effect sizes for CDAI or any outcome are reported in the abstract.,Primary outcome is not formally designated; the CDAI finding is an integration-analysis association, not a pre-specified primary efficacy endpoint with defined alpha level.,Short 8-week follow-up duration is insufficient to assess durability, relapse prevention, or long-term safety.,CDAI is a patient-reported symptom composite that does not capture endoscopic or histologic disease activity; absence of objective mucosal healing data limits clinical interpretation.,Surrogate biomarker endpoints (secondary bile acids, IL-10) are used to infer mechanism; whether these mediate or merely correlate with symptom improvement is not established.,Exclusion of participants taking common anti-inflammatory supplements and requirement for stable medication doses limit generalizability to a broad CD population.,Partial industry involvement (material supply by Hopsteiner and Metagenics) introduces potential non-financial conflict of interest.,Only the abstract was available for this review; full assessment of randomization fidelity, blinding integrity, dropout rates, and complete adverse event reporting is not possible. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ This small Phase 2 pilot RCT (n=19) generated a hypothesis-generating association between xanthohumol supplementation, reductions in gut secondary bile acids, elevations in IL-10, and improvement in CDAI scores in adults with active Crohn's disease. No inferential efficacy statistics are reported, and the study was not designed or powered to establish clinical benefit. Xanthohumol cannot be recommended as a therapeutic intervention for Crohn's disease on the basis of these findings; adequately powered, confirmatory trials with objective mucosal endpoints are required.